sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
ÒÆÖ²ÐÔÁܰÍÁö¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó > ÒÆÖ²ÐÔÁܰÍÁö¶¯ÎïÄ£×Ó

ǰÑÔ

ÁܰÍÁö(lymphoma)ÊDZ¬·¢ÓÚÁÜͶºÏ¼°£¨»ò£©ÁÜͶºÏÍâÁܰÍ×éÖ¯µÄ¶ñÐÔÖ×Áö£¬ÊÇÒ»Àà°üÀ¨¶àÖÖ²î±ðÁÙ´²ÌåÏֺͷÖ×ÓÉúÎïÑ§ÌØÕ÷µÄÖ×Áö¡£½üÄêÀ´£¬Ëæ×۬×̲¡¼°¼Ì·¢ÐÔÃâÒßÒÖÖÆ¼²²¡µÄÔö¶à£¬Æä·¢²¡ÂÊÔÚÌìϸ÷¹úÏÔ×ÅÉÏÉý£¬µ«Æä»ù´¡ºÍÁÙ´²Ñо¿Éî¶ÈºÍ¹ã¶ÈÈÔºÜÓÐÏÞ¡£½üÄêÀ´£¬ÈËÃÇÏà¼Ì½¨ÉèÖÖÖÖÁܰÍÁö¶¯ÎïÄ£×Ó£¬´Ó×Ô¾õÐÔ¡¢ÓÕ·¢ÐÔÖ×ÁöÄ£×Óµ½ÆÕ±éÔËÓõÄÒÆÖ²ÐÔÖ×ÁöÄ£×ÓÒÔ¼°ÔËÓ÷Ö×ÓÉúÎïѧÊÖÒÕ½¨ÉèµÄת»ùÒò¶¯ÎïÄ£×ӵȣ¬ÕâЩģ×ÓΪÉîÈëÑо¿ÁܰÍÁö²¡Òò¡¢·¢²¡»úÖÆ¡¢Õï¶ÏºÍÖÎÁƵÈÌṩÁËÓÐÓõÄÑо¿ÊֶΡ£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÓÃÒѽ¨ÉèµÄÁܰÍÁöϸ°ûÖê»ò»¼ÕßÁܰÍÁö×é֯ݪֲÓÚÃâÒßȱÏݶ¯ÎïÌåÄڿɽ¨ÉèÒÆÖ²ÐÔÁܰÍÁöÄ£×Ó£¬Õ¹ÏÖ¸ÃÖ×ÁöµÄÌØÕ÷£¬ÊÇÏÖÔÚÑо¿×î¶àµÄÖ×ÁöÄ£×Ó¡£ÏÖÔÚ£¬ÒÆÖ²ÐÔÁܰÍÁöÄ£×Óº£ÄÚÍâÖ÷Òª½ÓÄÉÒÔÏÂÁ½ÖÖÒÆÖ²ÒªÁ죺ϸ°ûݪֲ·¨ºÍ×éÖ¯¿éÒÆÖ²·¨¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.ϸ°ûݪֲ·¨ ÈËÁܰÍϸ°û(Raji)£¬1×106¸ö/Ö»£¬¸¹Ç»×¢ÉäÔÚ5~6ÖÜ´ÆÐÔBALB/c-nu/nuСÊó£¬Ò»Ñùƽ³£22Ìì×óÓÒ·ºÆðÏÔ×ŵĸ¹Ë®¡£ÈôÊǽÓÖÖϸ°ûÊýÄ¿ÔöÌí£¬·ºÆð¸¹Ë®µÄʱ¼ä»áËõ¶Ì¡£´ËÄ£×Ó¿ÉÒ»Á¬´«´ú£¬ÔÚÎÞ¾úÇéÐÎÏ£¬È¡ÂãÊóÒÆÖ²ÁöÖÆ³Éϸ°ûÐüÒº»ò¸¹Ë®Áöϸ°û¾ù¿É£¬ÀëÐĺóÓÃÔ­´úϸ°û°´ÒÔÉÏÒªÁì½ÓÖÖ£¬ÈÔ¿ÉÐγɸ¹Ë®¡£

2.×éÖ¯¿éԭλݪֲ·¨ È¡ÈËÔ­·¢ÐÔ½áÖ±³¦¶ñÐÔÁܰÍÁöÔ­·¢ÔîºÍ¸Î×ªÒÆÔîÊõÖÐÐÂÏÊÁö×éÖ¯¿é£¬¶ÔÊÜÌ嶯ÎïʵÑéÂé×í£¬È¡¸¹ÕýÖÐÏßÇпÚ£¬Ê¶±ð½áÖ±³¦£¬ÔÚ½¬Ä¤ÃæÏò³¦±ÚÄÚ×ö3mmÇпÚÉî´ïð¤Ä¤²ã£¬ÒÔ10.0ÎÞËðÉË·ìºÏÏß¾­Çпڽ«1mm3¾ÞϸµÄÁö×éÖ¯¿éÖ²ÈËÂãСÊó½áÖ±³¦ð¤Ä¤²ãÄÚ£¬Àο¿ÓÚ³¦±Úð¤Ä¤²ã£¬¹Ø¸¹·ìƤ¡£È»ºó¾ÙÐÐÌåÄÚԭλÆ÷¹Ùɸѡ£¬È¡Í³Ò»ÁöÔ´¸Î×ªÒÆÔî1mm3ÁöС¿éÒÆÖ²ÁíÒ»Ö»ÂãÊó½á³¦ð¤Ä¤²ã£¬³ÉÁöºóµÄ¸Î×ªÒÆÔîÒÆÖ²ÂãÊó½á³¦ð¤Ä¤²ã¡£ÔÚÂãÊóÌåÄÚÖØ¸´4´ÎÒ»Á¬É¸Ñ¡¡£È¡¸Î×ªÒÆÔî¾ÙÐÐÂãÊó½á³¦ÒÆÖ²£¬Êõºó¼ÌÐøËÇÑø£¬ÊÓ²ìÆÚΪ60~90Ìì¡£µ±ºÉÁöÂãÊó´¦ÓÚ±ôËÀ״̬ʱ£¬È¡ÆäÖÐ1Ö»ºÉÁöÂãÊóÓþ±×µÍÑλÊõÕý·¨£¬ÏµÍ³ÆÊ½â£¬È¡³öÒÆÖ²Áö¡£Ò»²¿·ÖÁö×éÖ¯ÒÔÔ­´úÒÆÖ²ÒªÁì¾ÙÐÐÊó¼äÒ»Á¬´«´ú£¬Ã¿´Î´«´ú5~10Ö»²»µÈ£»ÁíÒ»²¿·ÖÁö×éÖ¯Òºµª¶³´æ±¸Ó㬾ÙÐÐÏà¹ØÖ¸±ê¼ì²â¡£ÆäËûºÉÁöÂãÊóËÇÑøÖÁ±ôËÀ״̬»ò×ÔÈ»éæÃü£¬ÒÔÊÓ²ìÆäÖ×ÁöµÄÉú³¤¡¢ÇÖÏ®ºÍ×ªÒÆ¡£

¡¾Ä£×ÓÌØµã¡¿£º

1.ϸ°ûݪֲ·¨ Ä£×ÓÓи¹Ë®ÐγÉ£¬¶àÔò10ml×óÓÒ£¬¾µÏ¿ɼû´ó×ÚÁöϸ°û£¬ÇÒ¸¹Ç»ÄÚÓÐÁö¿é£¬Ö÷ÒªÂþÑܳ¦ÏµÄ¤£¬Ìù½ü³¦±Ú´¦¼°ÁÜͶºÏ½Ú£¬³¦ÏµÄ¤ÔöºñÕ³Á¬¼«ÎªÏÔ×Å¡£Áöϸ°û¾ÞϸһÖ£¬ºËȾɫÉºËÆÆËé¶à£¬÷缯ÅÅÁмäÖÊÉÙ£¬Áö½á½Ú»µËÀÏÔ×Å£¬Æ¢ÔàÎÞÏÔ׎þÈó£¬ÂËÅÝÔöÉú£¬Éú·¢ÖÐÐÄÏÔ×Å£¬¾ÞºËϸ°û¶à£¬¸Î¡¢Éö¡¢·Îδ¼ûÁöϸ°û½þÈó¡£È¾É«Ìå¼ì²éÏÔʾËùÓÐÖÐÆÚÏà¶à±¶ÌåÖУ¬×ÅË¿Á£´øÐÍÓëÈËȾɫÌåÒ»Ö£¬ÎªÈËÀàȾɫÌåÌØÕ÷¡£Ï¸°û½ÓÖÖÒªÁì³£Óø¹Ç»»òƤÏÂ×¢É䣬һÑùƽ³£À´Ëµ£¬½ÓÖÖÓÚÆ¤ÏµÄÄ£×Ó£¬ÓÉÓÚÆ¤·ôËÉи£¬Áö½á½Ú¿ÉÒԽϿìÉú³¤£¬ÏìÓ¦µÄËÞÖ÷ÊÙÃü½Ï³¤£¬±ãÓÚÑо¿ºÍÊӲ졣ӦÓóÉÐ͵Äϸ°ûϵעÉ䣬¿É½¨ÉèÄܹ»Ò»Á¬´«´úµÄBϸ°ûÁܰÍÁö¸¹Ç»Ä£×Ó£¬³ÉÁöÂÊ´ï100%¡£

2.×éÖ¯¿éԭλݪֲ·¨ ÕâÖÖÀàËÆÈ˽᳦¶ñÐÔÁܰÍÁö²¡µÄ¸ß×ªÒÆÄ£×ÓÒÆÖ²Áö²»µ«ÔÚ×éÖ¯²¡Àíѧ¡¢ÃâÒß×éÖ¯»¯Ñ§±íÐÍ¡¢³¬Î¢½á¹¹¡¢DNA±¶ÌåˮƽºÍȾɫÌåºËÐ͵ȷ½ÃæÓëÈËÔ´½áÖ±³¦¶ñÐÔÁܰÍÁöϸ°ûÏàÒ»Ö£¬²¢ÇÒÖ×ÁöµÄÒÆÖ²Éú³¤ÂʺÍÒºµª¶³´æËÕÐѳɻîÂʾùΪ100%¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

1.ÒÆÖ²ÐÔÖ×ÁöÄ£×ÓÊÇɸѡ¿¹Ö×ÁöÐÂÒ©×î³£Óõ͝ÎïÄ£×Ó¡£ÆäÓŵãÔÚÓÚÈÝÒײÙ×÷ºÍÊ©¼Ó×ÌÈÅÒòËØ£¬¶¯Îï³ÉÁöÎȹÌ£¬³ÉÁöÂʸߣ¬¸öÌå²î±ðС£¬³ÉÁöʱ¼ä²î±ð²»´ó£¬ÇÒ¿ÉÒÔͬÖÖ»òͬƷϵ¶¯ÎïÖÐÒ»Á¬ÒÆÖ²ºã¾Ã±£´æ¹©ÊÔÑéÖ®Ó᣿ÉÊÇ£¬´ËÀàÖ×ÁöÉú³¤ËÙÂʿ죬ÔöÖ³±ÈÂʸߣ¬Ìå»ý±¶Ôöʱ¼ä¶Ì£¬ÓëÈËÌåÖ×ÁöÏÔÖø²î±ð¡£

2.×Ô¾õÐÔ×ªÒÆÄ£×ÓÊÇÈ˰©×ªÒÆÄ£×ÓÑо¿ÁìÓòµÄÄÑÌ⣬ÉÏÊö×éÖ¯¿éԭλݪֲҪÁìÖÆ±¸µÄ×ªÒÆÄ£×Ó¾ßÓÐÎȹ̵ÄÉúÎïÑ§ÌØÕ÷£¬ÎªÑо¿Î¸³¦¶ñÐÔÁܰÍÁö×Ô¾õ×ªÒÆÌṩÁË»ù±¾µÄʵÑéÖÊÁÏ£»¸Ã·¨ÔÚÉîÈëÑо¿Ö±½á³¦¶ñÐÔÁܰÍÁöµÄÉúÎïÑ§ÌØÕ÷¡¢×éÖ¯±¬·¢¡¢²¡Òò²¡Àí¡¢ÇÖÏ®ºÍ×ªÒÆ»úÖÆ¡¢ÊµÑéÖÎÁƵȷ½ÃæÓв»¿ÉÈ¡´úµÄ×÷Óá£

 

²Î¿¼ÎÄÏ×£º

1.ÓÚÀ×£¬ÁõÓÀÕÜ£¬ËïÊÀÁú£¬µÈ£®c-myc»ùÒòÓë·øÉäÓÕ·¢Ð¡ÊóÐØÏÙÁܰÍÁöµÄ¹ØÁªÐÔÆÊÎö£®¼ªÁÖ´óѧѧ±¨£¨Ò½Ñ§°æ£©£¬2009, 35 (6):971-974

2.ÒüÖ¾»ª£¬ÌÚ·É£¬ÌÆÔËÁ«£¬µÈ£®»·æßËØA¶ÔÎȹÌEBVÓÕ·¢ÁܰÍÁöÄ£×ÓµÄ×÷ÓúÍÒâÒ壮ÖйúÃâÒßѧÔÓÖ¾£¬2002, 18(11):760-763

3.ÇñÑǾ꣬ÕÅÃ÷ÖÇ£¬ÀîÁᣮEB²¡¶¾ÓëÁܰÍÁö£®¹ú¼ÊÖ×ÁöѧÔÓÖ¾£¬2011, 38 (5):387-389

4.»Æ¸ñ·¼£¬ÓàÓ¢ºÀ£¬À£®N£­¼×»ùÑÇÏõ»ùëåÓÕµ¼Ð¡ÊóÐØÏÙÁܰÍÁöTCR»ùÒòÖØÅÅÆÊÎö£®Öйú½ÏÁ¿Ò½Ñ§ÔÓÖ¾£¬2010,20(9):7-11

5.Xu D,Wang S,Yu WM,et al. A germline gain-of­ function mutation in Ptpnl 1 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood,2010, 116(18):3611- 3621

6.Chen HJ.Yang BL,Chen YG,et al. A GFP-labeled human colon cancer metastasis model featuring surgical orthotopic implantation. Asian Pac J Cancer Prev, 2012, 13 (9):4263-4266

7.Chiarle R,Gong JZ,Guasparri¢ñ,et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood, 2003, 101 (5):1919-1927

8.Wang S, Yu WM, Zhang W, et al. Noonan syndrome/ leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN 11) enhance cell migration and angiogenesis. J Biol Chem,2009,284(2):913-920

9.Benavides F, Gomez  G, Venables-Griffith A, et al.Differential susceptibility to chemically induced thymic lymphomas in SENGARB and SSIN inbred mice. Mol Carcinog,2006,45 (7):543-548

10.da Silva Franchi CA,Bacchi MM,et al. Thymic lymphomas in Wistar rats exposed to N-methyl-N­ nitrosourea (MNU). Cancer Sci,2003,94(3):240-243

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó > ÒÆÖ²ÐÔÁܰÍÁö¶¯ÎïÄ£×Ó
ÒÆÖ²ÐÔÁܰÍÁö¶¯ÎïÄ£×Ó

ǰÑÔ

ÁܰÍÁö(lymphoma)ÊDZ¬·¢ÓÚÁÜͶºÏ¼°£¨»ò£©ÁÜͶºÏÍâÁܰÍ×éÖ¯µÄ¶ñÐÔÖ×Áö£¬ÊÇÒ»Àà°üÀ¨¶àÖÖ²î±ðÁÙ´²ÌåÏֺͷÖ×ÓÉúÎïÑ§ÌØÕ÷µÄÖ×Áö¡£½üÄêÀ´£¬Ëæ×۬×̲¡¼°¼Ì·¢ÐÔÃâÒßÒÖÖÆ¼²²¡µÄÔö¶à£¬Æä·¢²¡ÂÊÔÚÌìϸ÷¹úÏÔ×ÅÉÏÉý£¬µ«Æä»ù´¡ºÍÁÙ´²Ñо¿Éî¶ÈºÍ¹ã¶ÈÈÔºÜÓÐÏÞ¡£½üÄêÀ´£¬ÈËÃÇÏà¼Ì½¨ÉèÖÖÖÖÁܰÍÁö¶¯ÎïÄ£×Ó£¬´Ó×Ô¾õÐÔ¡¢ÓÕ·¢ÐÔÖ×ÁöÄ£×Óµ½ÆÕ±éÔËÓõÄÒÆÖ²ÐÔÖ×ÁöÄ£×ÓÒÔ¼°ÔËÓ÷Ö×ÓÉúÎïѧÊÖÒÕ½¨ÉèµÄת»ùÒò¶¯ÎïÄ£×ӵȣ¬ÕâЩģ×ÓΪÉîÈëÑо¿ÁܰÍÁö²¡Òò¡¢·¢²¡»úÖÆ¡¢Õï¶ÏºÍÖÎÁƵÈÌṩÁËÓÐÓõÄÑо¿ÊֶΡ£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÓÃÒѽ¨ÉèµÄÁܰÍÁöϸ°ûÖê»ò»¼ÕßÁܰÍÁö×é֯ݪֲÓÚÃâÒßȱÏݶ¯ÎïÌåÄڿɽ¨ÉèÒÆÖ²ÐÔÁܰÍÁöÄ£×Ó£¬Õ¹ÏÖ¸ÃÖ×ÁöµÄÌØÕ÷£¬ÊÇÏÖÔÚÑо¿×î¶àµÄÖ×ÁöÄ£×Ó¡£ÏÖÔÚ£¬ÒÆÖ²ÐÔÁܰÍÁöÄ£×Óº£ÄÚÍâÖ÷Òª½ÓÄÉÒÔÏÂÁ½ÖÖÒÆÖ²ÒªÁ죺ϸ°ûݪֲ·¨ºÍ×éÖ¯¿éÒÆÖ²·¨¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.ϸ°ûݪֲ·¨ ÈËÁܰÍϸ°û(Raji)£¬1×106¸ö/Ö»£¬¸¹Ç»×¢ÉäÔÚ5~6ÖÜ´ÆÐÔBALB/c-nu/nuСÊó£¬Ò»Ñùƽ³£22Ìì×óÓÒ·ºÆðÏÔ×ŵĸ¹Ë®¡£ÈôÊǽÓÖÖϸ°ûÊýÄ¿ÔöÌí£¬·ºÆð¸¹Ë®µÄʱ¼ä»áËõ¶Ì¡£´ËÄ£×Ó¿ÉÒ»Á¬´«´ú£¬ÔÚÎÞ¾úÇéÐÎÏ£¬È¡ÂãÊóÒÆÖ²ÁöÖÆ³Éϸ°ûÐüÒº»ò¸¹Ë®Áöϸ°û¾ù¿É£¬ÀëÐĺóÓÃÔ­´úϸ°û°´ÒÔÉÏÒªÁì½ÓÖÖ£¬ÈÔ¿ÉÐγɸ¹Ë®¡£

2.×éÖ¯¿éԭλݪֲ·¨ È¡ÈËÔ­·¢ÐÔ½áÖ±³¦¶ñÐÔÁܰÍÁöÔ­·¢ÔîºÍ¸Î×ªÒÆÔîÊõÖÐÐÂÏÊÁö×éÖ¯¿é£¬¶ÔÊÜÌ嶯ÎïʵÑéÂé×í£¬È¡¸¹ÕýÖÐÏßÇпÚ£¬Ê¶±ð½áÖ±³¦£¬ÔÚ½¬Ä¤ÃæÏò³¦±ÚÄÚ×ö3mmÇпÚÉî´ïð¤Ä¤²ã£¬ÒÔ10.0ÎÞËðÉË·ìºÏÏß¾­Çпڽ«1mm3¾ÞϸµÄÁö×éÖ¯¿éÖ²ÈËÂãСÊó½áÖ±³¦ð¤Ä¤²ãÄÚ£¬Àο¿ÓÚ³¦±Úð¤Ä¤²ã£¬¹Ø¸¹·ìƤ¡£È»ºó¾ÙÐÐÌåÄÚԭλÆ÷¹Ùɸѡ£¬È¡Í³Ò»ÁöÔ´¸Î×ªÒÆÔî1mm3ÁöС¿éÒÆÖ²ÁíÒ»Ö»ÂãÊó½á³¦ð¤Ä¤²ã£¬³ÉÁöºóµÄ¸Î×ªÒÆÔîÒÆÖ²ÂãÊó½á³¦ð¤Ä¤²ã¡£ÔÚÂãÊóÌåÄÚÖØ¸´4´ÎÒ»Á¬É¸Ñ¡¡£È¡¸Î×ªÒÆÔî¾ÙÐÐÂãÊó½á³¦ÒÆÖ²£¬Êõºó¼ÌÐøËÇÑø£¬ÊÓ²ìÆÚΪ60~90Ìì¡£µ±ºÉÁöÂãÊó´¦ÓÚ±ôËÀ״̬ʱ£¬È¡ÆäÖÐ1Ö»ºÉÁöÂãÊóÓþ±×µÍÑλÊõÕý·¨£¬ÏµÍ³ÆÊ½â£¬È¡³öÒÆÖ²Áö¡£Ò»²¿·ÖÁö×éÖ¯ÒÔÔ­´úÒÆÖ²ÒªÁì¾ÙÐÐÊó¼äÒ»Á¬´«´ú£¬Ã¿´Î´«´ú5~10Ö»²»µÈ£»ÁíÒ»²¿·ÖÁö×éÖ¯Òºµª¶³´æ±¸Ó㬾ÙÐÐÏà¹ØÖ¸±ê¼ì²â¡£ÆäËûºÉÁöÂãÊóËÇÑøÖÁ±ôËÀ״̬»ò×ÔÈ»éæÃü£¬ÒÔÊÓ²ìÆäÖ×ÁöµÄÉú³¤¡¢ÇÖÏ®ºÍ×ªÒÆ¡£

¡¾Ä£×ÓÌØµã¡¿£º

1.ϸ°ûݪֲ·¨ Ä£×ÓÓи¹Ë®ÐγÉ£¬¶àÔò10ml×óÓÒ£¬¾µÏ¿ɼû´ó×ÚÁöϸ°û£¬ÇÒ¸¹Ç»ÄÚÓÐÁö¿é£¬Ö÷ÒªÂþÑܳ¦ÏµÄ¤£¬Ìù½ü³¦±Ú´¦¼°ÁÜͶºÏ½Ú£¬³¦ÏµÄ¤ÔöºñÕ³Á¬¼«ÎªÏÔ×Å¡£Áöϸ°û¾ÞϸһÖ£¬ºËȾɫÉºËÆÆËé¶à£¬÷缯ÅÅÁмäÖÊÉÙ£¬Áö½á½Ú»µËÀÏÔ×Å£¬Æ¢ÔàÎÞÏÔ׎þÈó£¬ÂËÅÝÔöÉú£¬Éú·¢ÖÐÐÄÏÔ×Å£¬¾ÞºËϸ°û¶à£¬¸Î¡¢Éö¡¢·Îδ¼ûÁöϸ°û½þÈó¡£È¾É«Ìå¼ì²éÏÔʾËùÓÐÖÐÆÚÏà¶à±¶ÌåÖУ¬×ÅË¿Á£´øÐÍÓëÈËȾɫÌåÒ»Ö£¬ÎªÈËÀàȾɫÌåÌØÕ÷¡£Ï¸°û½ÓÖÖÒªÁì³£Óø¹Ç»»òƤÏÂ×¢É䣬һÑùƽ³£À´Ëµ£¬½ÓÖÖÓÚÆ¤ÏµÄÄ£×Ó£¬ÓÉÓÚÆ¤·ôËÉи£¬Áö½á½Ú¿ÉÒԽϿìÉú³¤£¬ÏìÓ¦µÄËÞÖ÷ÊÙÃü½Ï³¤£¬±ãÓÚÑо¿ºÍÊӲ졣ӦÓóÉÐ͵Äϸ°ûϵעÉ䣬¿É½¨ÉèÄܹ»Ò»Á¬´«´úµÄBϸ°ûÁܰÍÁö¸¹Ç»Ä£×Ó£¬³ÉÁöÂÊ´ï100%¡£

2.×éÖ¯¿éԭλݪֲ·¨ ÕâÖÖÀàËÆÈ˽᳦¶ñÐÔÁܰÍÁö²¡µÄ¸ß×ªÒÆÄ£×ÓÒÆÖ²Áö²»µ«ÔÚ×éÖ¯²¡Àíѧ¡¢ÃâÒß×éÖ¯»¯Ñ§±íÐÍ¡¢³¬Î¢½á¹¹¡¢DNA±¶ÌåˮƽºÍȾɫÌåºËÐ͵ȷ½ÃæÓëÈËÔ´½áÖ±³¦¶ñÐÔÁܰÍÁöϸ°ûÏàÒ»Ö£¬²¢ÇÒÖ×ÁöµÄÒÆÖ²Éú³¤ÂʺÍÒºµª¶³´æËÕÐѳɻîÂʾùΪ100%¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

1.ÒÆÖ²ÐÔÖ×ÁöÄ£×ÓÊÇɸѡ¿¹Ö×ÁöÐÂÒ©×î³£Óõ͝ÎïÄ£×Ó¡£ÆäÓŵãÔÚÓÚÈÝÒײÙ×÷ºÍÊ©¼Ó×ÌÈÅÒòËØ£¬¶¯Îï³ÉÁöÎȹÌ£¬³ÉÁöÂʸߣ¬¸öÌå²î±ðС£¬³ÉÁöʱ¼ä²î±ð²»´ó£¬ÇÒ¿ÉÒÔͬÖÖ»òͬƷϵ¶¯ÎïÖÐÒ»Á¬ÒÆÖ²ºã¾Ã±£´æ¹©ÊÔÑéÖ®Ó᣿ÉÊÇ£¬´ËÀàÖ×ÁöÉú³¤ËÙÂʿ죬ÔöÖ³±ÈÂʸߣ¬Ìå»ý±¶Ôöʱ¼ä¶Ì£¬ÓëÈËÌåÖ×ÁöÏÔÖø²î±ð¡£

2.×Ô¾õÐÔ×ªÒÆÄ£×ÓÊÇÈ˰©×ªÒÆÄ£×ÓÑо¿ÁìÓòµÄÄÑÌ⣬ÉÏÊö×éÖ¯¿éԭλݪֲҪÁìÖÆ±¸µÄ×ªÒÆÄ£×Ó¾ßÓÐÎȹ̵ÄÉúÎïÑ§ÌØÕ÷£¬ÎªÑо¿Î¸³¦¶ñÐÔÁܰÍÁö×Ô¾õ×ªÒÆÌṩÁË»ù±¾µÄʵÑéÖÊÁÏ£»¸Ã·¨ÔÚÉîÈëÑо¿Ö±½á³¦¶ñÐÔÁܰÍÁöµÄÉúÎïÑ§ÌØÕ÷¡¢×éÖ¯±¬·¢¡¢²¡Òò²¡Àí¡¢ÇÖÏ®ºÍ×ªÒÆ»úÖÆ¡¢ÊµÑéÖÎÁƵȷ½ÃæÓв»¿ÉÈ¡´úµÄ×÷Óá£

 

²Î¿¼ÎÄÏ×£º

1.ÓÚÀ×£¬ÁõÓÀÕÜ£¬ËïÊÀÁú£¬µÈ£®c-myc»ùÒòÓë·øÉäÓÕ·¢Ð¡ÊóÐØÏÙÁܰÍÁöµÄ¹ØÁªÐÔÆÊÎö£®¼ªÁÖ´óѧѧ±¨£¨Ò½Ñ§°æ£©£¬2009, 35 (6):971-974

2.ÒüÖ¾»ª£¬ÌÚ·É£¬ÌÆÔËÁ«£¬µÈ£®»·æßËØA¶ÔÎȹÌEBVÓÕ·¢ÁܰÍÁöÄ£×ÓµÄ×÷ÓúÍÒâÒ壮ÖйúÃâÒßѧÔÓÖ¾£¬2002, 18(11):760-763

3.ÇñÑǾ꣬ÕÅÃ÷ÖÇ£¬ÀîÁᣮEB²¡¶¾ÓëÁܰÍÁö£®¹ú¼ÊÖ×ÁöѧÔÓÖ¾£¬2011, 38 (5):387-389

4.»Æ¸ñ·¼£¬ÓàÓ¢ºÀ£¬À£®N£­¼×»ùÑÇÏõ»ùëåÓÕµ¼Ð¡ÊóÐØÏÙÁܰÍÁöTCR»ùÒòÖØÅÅÆÊÎö£®Öйú½ÏÁ¿Ò½Ñ§ÔÓÖ¾£¬2010,20(9):7-11

5.Xu D,Wang S,Yu WM,et al. A germline gain-of­ function mutation in Ptpnl 1 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood,2010, 116(18):3611- 3621

6.Chen HJ.Yang BL,Chen YG,et al. A GFP-labeled human colon cancer metastasis model featuring surgical orthotopic implantation. Asian Pac J Cancer Prev, 2012, 13 (9):4263-4266

7.Chiarle R,Gong JZ,Guasparri¢ñ,et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood, 2003, 101 (5):1919-1927

8.Wang S, Yu WM, Zhang W, et al. Noonan syndrome/ leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN 11) enhance cell migration and angiogenesis. J Biol Chem,2009,284(2):913-920

9.Benavides F, Gomez  G, Venables-Griffith A, et al.Differential susceptibility to chemically induced thymic lymphomas in SENGARB and SSIN inbred mice. Mol Carcinog,2006,45 (7):543-548

10.da Silva Franchi CA,Bacchi MM,et al. Thymic lymphomas in Wistar rats exposed to N-methyl-N­ nitrosourea (MNU). Cancer Sci,2003,94(3):240-243

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿